ArticleToxics2026
Association of Maternal Bone Resorption with Urinary Fluoride Levels During Pregnancy.
Article in Toxics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Evidence is accumulating linking prenatal fluoride exposure with adverse neurodevelopment. Maternal urinary fluoride (MUF) is a well-established biomarker of fluoride exposure. Because most fluoride is stored in calcified tissues, pregnancy-associated changes in bone metabolism may contribute to fetal fluoride exposure. We evaluated whether maternal bone resorption, indexed by urinary N-telopeptide of type I collagen (NTX), is associated with MUF across pregnancy. Participants were drawn from the Early Life Exposures in Mexico to Environmental Toxicants (ELEMENT) birth cohorts. Each woman contributed one paired MUF-NTX measurement per trimester. Both biomarkers were creatinine-normalized to account for urine dilution. Trimester-specific generalized linear models with a Gamma distribution estimated associations between NTX and MUF, adjusting for maternal age, birth order, infant birthweight, and cohort. Across the trimesters, MUF was relatively stable (0.89 ± 0.37, 0.91 ± 0.41, and 0.83 ± 0.42 mg/L), whereas NTX increased with gestation (68.0 ± 33.5, 99.0 ± 50.3, and 132.4 ± 65.4 nmol BCE/mM creatinine). Higher NTX was consistently associated with higher MUF: β = 0.00315 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.